Additional file 2 of Curation of the Fasciola hepatica kinome as a resource for drug target discovery

Additional file 2: Supplementary data 2. Supplementary Figs. 1–10 depict a phylogenetic tree of each individual PK group including the posterior probabilities: AGC (Supplementary Fig. 1), Atypical (Supplementary Fig. 2), CAMK (Supplementary Fig. 3), CK1 (Supplementary Fig. 4), CMGC (Supplementary Fig. 5), Others (Supplementary Fig. 6), RGC (Supplementary Fig. 7), STE (Supplementary Fig. 8), TK (Supplementary Fig. 9), and TKL (Supplementary Fig. 10). Supplementary Fig. 11 depicts a phylogenetic tree for the STE11-family member D915_005277 and Supplementary Fig. 12 depicts a phylogenetic tree for the CAMK-family member D915_001682. Supplementary Tables 1–5: Statistical data on motility scores of the treated adult and immature flukes depicted in Fig. 5. Suppl. Table 1: The statistical values for control vs. vandetanib treated adult and immature flukes. Table 2: The statistical values for control vs. foretinib treated adult and immature flukes. Table 3: The statistical values for control vs. tyrosine kinase-IN-1 treated adult and immature flukes. Table 4: The statistical values for control vs. ruboxistaurin treated adult and immature flukes. Table 5: The statistical values for control vs. triclabendazole treated adult and immature flukes. Table 6: The clinical trial status of protein kinase inhibitor used in vitro against immature and adult flukes.